Digitisation | August 11, 2021
Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
The aim is to create new genomics solutions that could combat cancer and advance market access
The aim is to create new genomics solutions that could combat cancer and advance market access
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
